AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq ... compared with standard care. AZ is still pressing on with development of Imfinzi ...
The green light from the European Commission means that Enhertu (trastuzumab deruxtecan) can now be used for patients whose disease has progressed after first-line therapies such as Roche’s ...
El Conquistador Tucson A Hilton Resort, Roche Tissue Diagnostics, Arizona Pristine Roofing, Natural Grocers and Skratch Labs. Net proceeds benefit St. Luke’s Home, which provides aid to low ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback